Abstract |
Drug delivery vehicles are often assessed for their ability to control primary tumor growth, but the outcome of cancer treatment depends on controlling or inhibiting metastasis. Therefore, we studied the efficacy of our genetically encoded polypeptide nanoparticle for doxorubicin delivery (CP-Dox) in the syngeneic metastatic murine models 4T1 and Lewis lung carcinoma. We found that our nanoparticle formulation increased the half-life, maximum tolerated dose, and tumor accumulation of doxorubicin. When drug treatment was combined with primary tumor resection, greater than 60% of the mice were cured in both the 4T1 and Lewis lung carcinoma models compared to 20% treated with free drug. Mechanistic studies suggest that metastasis inhibition and survival increase were achieved by preventing the dissemination of viable tumor cells from the primary tumor.
|
Authors | Eric M Mastria, Mingnan Chen, Jonathan R McDaniel, Xinghai Li, Jinho Hyun, Mark W Dewhirst, Ashutosh Chilkoti |
Journal | Journal of controlled release : official journal of the Controlled Release Society
(J Control Release)
Vol. 208
Pg. 52-8
(Jun 28 2015)
ISSN: 1873-4995 [Electronic] Netherlands |
PMID | 25637704
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2015 Elsevier B.V. All rights reserved. |
Chemical References |
- Antibiotics, Antineoplastic
- Peptides
- Doxorubicin
|
Topics |
- Animals
- Antibiotics, Antineoplastic
(administration & dosage, pharmacokinetics, therapeutic use)
- Body Weight
(drug effects)
- Carcinoma
(drug therapy)
- Carcinoma, Lewis Lung
(drug therapy)
- Doxorubicin
(administration & dosage, pharmacokinetics, therapeutic use)
- Drug Delivery Systems
- Half-Life
- Maximum Tolerated Dose
- Mice
- Mice, Inbred BALB C
- Nanoparticles
(chemistry)
- Neoplasm Metastasis
(drug therapy, pathology)
- Neoplasms, Experimental
(drug therapy)
- Peptides
(chemistry)
- Survival Analysis
- Tissue Distribution
|